Navigation Links
Study uncovers why anti-rejection drugs for transplant patients cause hypertension
Date:10/7/2011

PORTLAND, Ore. Modern medicine's ability to save lives through organ transplantation has been revolutionized by the development of drugs that prevent the human body from rejecting the transplanted organ.

But those antirejection drugs have their own side effects sometimes serious.

A group of researchers led by scientists at Oregon Health & Science University has discovered the process that may be causing many of those side effects. And the discovery means those side effects likely can be dealt with cheaply and easily with a class of widely used drugs that are often avoided in patients with organ transplants.

The researchers' findings were published this week in the online edition of the journal Nature Medicine.

The researchers examined the effects of a class of antirejection or immunosuppressive drugs called calcineurin inhibitors, which includes cyclosporine and tacrolimus.

Calcineurin inhibitors, which can be instrumental in preventing organ rejection in transplant patients, also can cause hypertension and kidney problems. The researchers' findings reveal what ultimately causes those problems a calcineurin inhibitor spurs the production of an abnormally high level of a natural protein in the kidney.

Researchers found that a thiazide diuretic drug, which blocks the responsible protein, reduced hypertension in mice that had been given the calcineurin inhibitor. And mice lacking this protein did not develop hypertension at all.

The collaborative team of researchers, which included scientists from University College London, extended their observations to humans kidney transplant patients in the United Kingdom.

University College London scientists found that kidney transplant patients who received the calcineurin inhibitor were more sensitive to a thiazide diuretic than were patients treated with other antirejection drugs.

The research results could mean very good news for transplant patients who have hypertension and potassium problems due to the antirejection drugs they're taking. That's because the drugs that can combat the elevation of the natural protein are generally the cheapest hypertensive drugs available but many physicians have not been prescribing them for the side effects because they believed the problems were caused by changes outside the kidney.

"These findings should allow physicians to prescribe these simple drugs much more often and provide help to many, many more transplant patients who are suffering from these side effects," said David Ellison, M.D., head of OHSU's Division of Nephrology and Hypertension and the senior author of the study.

Ellison said the research points the way toward the next question he is planning to look at taking a deeper look at the mechanism of how the antirejection drugs work. More research in that area might help scientists develop a drug that suppresses the body's attempt to reject a transplanted organ, but produces none of the hypertension and other side effects, he said.

"That's my new grant proposal to take it to the next step," Ellison said.

The lead investigators on the study were a nephrology trainee from Erasmus University in The Netherlands who worked for six months in Ellison's laboratory, and an honorary senior lecturer from UCL. Scientists from Charit University in Berlin, Germany, also contributed substantially.

"This was a great example of team science," Ellison said. "It was fun to have people from around the world collaborate to produce something that none of them was capable of producing alone."


'/>"/>

Contact: Todd Murphy
murphyt@ohsu.edu
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Study finds liver cancer increasing in low risk countries, decreasing in high risk countries
2. Oxygenating Blood of Hospitalized H1N1 Flu Patients Saved Lives: Study
3. National Study Will Track Tobacco Use in U.S.
4. Many Medicare Patients Get Surgeries in Last Year of Life: Study
5. FDA and NIH announce joint study on tobacco use and risk perceptions
6. MRI Safe With More Recent Defibrillators, Pacemakers: Study
7. Nursing Homes Not Meeting Flu-Shot Goals, Study Says
8. Virginia Commonwealth University study: We are what we experience
9. New study shows inflammatory food toxins found in high levels in infants
10. Wayne State University to study effects of risky family environments on childhood asthma
11. Overnight Stay May Not Be Necessary for Stenting: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
(Date:2/5/2016)... ... ... Health and wellness is a topic that should concern all Americans; however, it ... illness. Migraines are a severe form of a headache and often are accompanied by ... pain on their worst enemy, the feeling can last for many hours and be ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just been updated ... interface design and the developer has fixed known bugs within the app. Calls Blacklist ... their phone while not consuming any of their device’s battery power or memory. It ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Calif. , Feb. 5, 2016 Amgen (NASDAQ: ... th Annual Global Healthcare Conference at 9:15 a.m. ET ... City . David W. Meline , executive vice ... the conference. Live audio of the presentation can be accessed ... under Investors. A replay of the webcast will also be ...
(Date:2/5/2016)... a medical devices company, is one of five recipients to ... Terry McAuliffe,s office. ivWatch will be receiving the STEM ... to be held at the Science Museum of ... that have made significant contributions to science. ... ivWatch ...
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
Breaking Medicine Technology: